Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
about
Prognosis and management of acute myeloid leukemia in patients with Down syndromeMassive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21.Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature ReviewAdvances in paediatric cancer treatmentPharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.Malignancy in children with trisomy 21.Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology GroupChildren's Oncology Group's 2013 blueprint for research: acute myeloid leukemiaOverview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group.Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group.Risk factors for early death in neonates with Down syndrome and transient leukaemia.Acute myeloid leukemia in children: Current status and future directions.Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome.
P2860
Q27016577-2604865D-6A68-4B59-A29A-586B28357E77Q33886396-524B1979-8218-4917-B587-7A3F8A52FF0AQ35888110-8C3F1D57-F655-48C2-9D2C-5A28E4BD53CFQ36508630-A629D67C-AA12-49D8-8853-C5D0BAC41199Q36828315-64C9C304-37B4-4A47-B98A-A898C6232B73Q37059586-69BBE7FC-2A72-4EC3-9469-9C55046C290EQ37379570-FC1E4897-7E17-4549-BA48-CA7CD4E44433Q37427903-8DFEA943-CEDD-4AEA-BB17-B0094115D66BQ38068816-258311DE-FCE5-4C79-8BDC-4C45D08667EDQ38196743-8BA049AF-EE34-470B-88C9-443FC98AF2A2Q38915719-46AED9E4-2B1D-45D3-98B0-30491CF1B038Q40446750-4481B014-6E55-4DFA-85CC-C7359620D6A4Q41203406-ED8BCBF3-31B4-43B3-9792-152BCC78A693Q42012900-C497E01E-A466-48B2-93AC-C6D771AA38FFQ46569123-F0FC172F-11FA-4E2C-8FDA-18A5285BE18CQ52897332-DFCF93D0-D786-4EA0-8130-6E57EB05157AQ54494977-DEF4B740-AD9A-4C61-A289-05DC2D7DF786
P2860
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Optimal treatment intensity in ...... nd a review of the literature.
@ast
Optimal treatment intensity in ...... nd a review of the literature.
@en
type
label
Optimal treatment intensity in ...... nd a review of the literature.
@ast
Optimal treatment intensity in ...... nd a review of the literature.
@en
prefLabel
Optimal treatment intensity in ...... nd a review of the literature.
@ast
Optimal treatment intensity in ...... nd a review of the literature.
@en
P2093
P1433
P1476
Optimal treatment intensity in ...... nd a review of the literature.
@en
P2093
Bernward Zeller
Eva Ellebaek
Gudmundur Jonmundsson
Göran Gustafsson
Jonas Abrahamsson
Liisa Hovi
Lotte Abildgaard
P304
P356
10.1007/S00277-005-0045-5
P50
P577
2006-03-04T00:00:00Z